Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 3/2012

01-03-2012 | Original Article

Adherence to osteoporosis medications amongst Singaporean patients

Authors: M. H. H. Cheen, M. C. Kong, R. F. Zhang, F. M. H. Tee, M. Chandran

Published in: Osteoporosis International | Issue 3/2012

Login to get access

Abstract

Summary

Compliance and persistence to bisphosphonates amongst Singaporean patients with osteoporosis were estimated. Mean medication possession ratio (MPR) ± standard deviation (SD) was 78.9 ± 27.5%, and 69.0% was persistent at 1 year. In contrast to US and Europe where poor adherence is noted, our study suggests higher adherence rates to bisphosphonate therapy amongst patients.

Introduction

Adherence to bisphosphonate therapy during treatment of osteoporosis has been reported to be poor. We aimed to estimate the compliance and persistence to prescribed bisphosphonate therapy amongst patients at the largest public restructured hospital in Singapore.

Methods

This is a retrospective analysis of records of patients who were prescribed the two most commonly used oral bisphosphonates—alendronate and risedronate. The study was conducted between January 2007 and December 2008. Prescription and pharmacy refill records of all patients were extracted and matched. Compliance was calculated using the MPR, while persistence, a dichotomous variable, was defined as continuous refill of bisphosphonates for at least 12 months with a permissible gap of 30 days.

Results

Seven hundred ninety-eight patients were included in the study. Mean MPR ± SD was 78.9 ± 27.5%, and 69.0% of the patients were persistent with bisphosphonate therapy at 1 year. The proportion of patients with MPR ≥80% at 6, 12 and 18 months was 90%, 72% and 62%, respectively. Age <69 years was associated with better compliance (OR, 1.34; 95% CI, 0.99–1.82; P = 0.043), and history of fractures was associated with better compliance (OR, 1.38; 95% CI, 1.02–1.87; P = 0.038) and persistence (OR, 1.33; 95% CI, 0.97–1.82; P = 0.046).

Conclusion

In contrast to studies conducted in the US and Europe that show poor adherence, our study suggests higher adherence rates to bisphosphonate therapy amongst Singaporean patients.
Literature
1.
Ministry of Health (2009) Osteoporosis clinical practice guidelines. Ministry of Health, Singapore, p 82 (Jan)
2.
3.
Leong KH (1998) Osteoporosis—the need for a paradigm shift. Ann Acad Med Singapore 27(1):100–104PubMed
4.
Lee AY, Chua BS, Howe TS (2007) One-year outcome of hip fracture patients admitted to a Singapore hospital: quality of life post-treatment. Singapore Med J 48(11):996–999PubMed
5.
Wong MK et al (2002) Osteoporotic hip fractures in Singapore—costs and patient's outcome. Ann Acad Med Singapore 31(1):3–7PubMed
6.
Chen LT et al (2007) Hip fractures in the elderly: the impact of comorbid illnesses on hospitalisation costs. Ann Acad Med Singapore 36(9):784–787PubMed
7.
Miller NH (1997) Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 102(2A):43–49PubMedCrossRef
8.
World Health Organization (2003) Adherence to long-term therapies: evidence for action. World Health Organization, Geneva
9.
Solomon DH et al (2005) Compliance with osteoporosis medications. Arch Intern Med 165(20):2414–2419PubMedCrossRef
10.
Boccuzzi S, Foltz S, Omar M (2005) Assessment of adherence and persistance with daily and weekly dosing regimens of oral bisphosphonates. Osteoporos Int 16:S35–S36
11.
Cramer JA et al (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21(9):1453–1460PubMedCrossRef
12.
Weycker D, Macarios D, Oster G (2005) Adherence with weekly versus daily bisphosphonate therapy among women with postmenopausal osteoporosis. J Bone Miner Res 20(suppl 1):2
13.
Loong TW (1999) Primary non-compliance in a Singapore polyclinic. Singapore Med J 40(11):691–693PubMed
14.
Siris ES et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81(8):1013–1022PubMedCrossRef
15.
Rabenda V, Hiligsmann M, Reginster JY (2009) Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother 10(14):2303–2315PubMedCrossRef
16.
Curtis JR et al (2008) Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 23(9):1435–1441PubMedCrossRef
17.
Cotte FE et al (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21(1):145–155PubMedCrossRef
18.
Amanda RP et al (2010) The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab 95(7):9
19.
Netelenbos JC et al (2010) Adherence and profile of non-persistence in patients treated for osteoporosis-a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int (in press)
20.
Pasion EG et al (2007) Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women. J Bone Miner Metab 25(2):105–113PubMedCrossRef
21.
Hess LM et al (2006) Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 40(7–8):1280–1288PubMed
22.
Cramer JA et al (2008) Medication compliance and persistence: terminology and definitions. Value Health 11(1):44–47PubMedCrossRef
23.
Yeaw J et al (2009) Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15(9):728–740PubMed
24.
Caro JJ et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15(12):1003–1008PubMedCrossRef
25.
Papaioannou A et al (2003) Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14(10):808–813PubMedCrossRef
26.
Yood RA et al (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14(12):965–968PubMedCrossRef
27.
Grossberg R, Zhang Y, Gross R (2004) A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol 57(10):1107–1110PubMedCrossRef
28.
Curtis JR et al (2006) Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. Pharmacoepidemiol Drug Saf 15(10):710–718PubMedCrossRef
29.
Brankin E et al (2006) The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 22(7):1249–1256PubMedCrossRef
30.
Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38(6):922–928PubMedCrossRef
31.
McCombs JS et al (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48(3):271–287PubMedCrossRef
32.
Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89(3):1117–1123PubMedCrossRef
33.
Rabenda V et al (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19(6):811–818PubMedCrossRef
34.
World Health Organization (2000) Health systems performance. World Health Organization, Geneva
35.
36.
Hiligsmann M et al (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86(3):202–210PubMedCrossRef
37.
Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80(7):856–861PubMedCrossRef
38.
Elizabeth ER et al (2009) Medication adherence, first episode duration, overall duration and time without therapy: the example of bisphosphonates. Pharmacoepidemiol Drug Saf 18:7CrossRef
39.
Lo JC et al (2006) Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 17(6):922–928PubMedCrossRef
40.
Farmer KC (1999) Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 21(6):1074–1090, discussion 1073PubMedCrossRef
41.
Steiner JF, Prochazka AV (1997) The assessment of refill compliance using pharmacy records: methods, validity, and application. J Clin Epidemiol 50:12CrossRef
42.
Sikka R, Xia F, Aubert RE (2005) Estimating medication persistency using administrative claims data. Am J Manag Care 11:9
43.
Gleeson T et al (2009) Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 20(12):2127–2134PubMedCrossRef
Metadata
Title
Adherence to osteoporosis medications amongst Singaporean patients
Authors
M. H. H. Cheen
M. C. Kong
R. F. Zhang
F. M. H. Tee
M. Chandran
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 3/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-011-1635-9

Other articles of this Issue 3/2012

Osteoporosis International 3/2012 Go to the issue

Original Article

Predictive values of calcaneal quantitative ultrasound and dual energy X ray absorptiometry for non-vertebral fracture in older men: results from the MrOS study (Hong Kong)

Original Article

Comparative trends in hospitalizations for osteoporotic fractures and other frequent diseases between 2000 and 2008

Original Article

The post-fracture care gap among Canadian First Nations peoples: a retrospective cohort study

Short Communication

Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide

Original Article

Estimation of the lifetime risk of hip fracture for women and men in Canada

Original Article

Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta